1. Home
  2. CIBINQO (abrocitinib)

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.1

Powerful Skin Clearance and Rapid Itch Relief

EASI-75 at week 12 and PP-NRS4 as early as week 2 achieved for some patients

See Efficacy Data
Flexibility to Increase or Decrease Dose if Needed

CIBINQO is an oral, once-daily treatment


See Dosing
Well-studied Safety Profile in AD Population

Studied in 3582 patients with AD across multiple clinical trials


See Safety Information

AD=atopic dermatitis; EASI-75= ≥75% improvement in lesion extent and severity from baseline on the Eczema Area and Severity Index; PP-NRS4= ≥4-point reduction from baseline on the Peak Pruritus Numerical Rating Scale.



References:

  1. Cibinqo (abrocitinib) latest approved Isareli prescribing information.